Blau Farmaceutica stock falls 2.47 percent on B3

Blau Farmaceutica stock was at BRL 10.26 on B3 on September 24, 2026, down 2.47 percent. The latest quarterly figures show revenue of BRL 486.60 million and net income of BRL 53.39 million in Q2 2026.

Q2 revenue rises 11.87 percent

Investing.com reports Q2 revenue of BRL 486.60 million, compared with BRL 434.97 million in Q1 2026. That is an increase of 11.87 percent and gives the company a clear sequential growth signal.

Net income reached BRL 53.39 million in Q2, versus BRL 39.77 million in Q1. The increase of 34.26 percent was stronger than the revenue gain, indicating that earnings growth outpaced sales growth during the first half of 2026.

Profit growth outpaces sales

The margin picture is important because Blau operates in specialty and complex hospital pharmaceuticals, where product mix and production efficiency can materially affect earnings. Q2 gross profit was BRL 201.95 million on revenue of BRL 486.60 million, equivalent to a 41.50 percent gross margin.

Blau's investor relations page describes four business units: Biotechnology, Oncology, Specialty and Others. The mix gives the company exposure to hospital medicines, biological products and oncology therapies rather than relying on a single drug category.

Free float deadline moves to 2027

A separate corporate development came on September 9, 2026, when TipRanks reported that B3 granted Blau an automatic one-year extension to meet the minimum free float requirement. The deadline moved from December 31, 2026 to December 31, 2027.

The extension changes the timing of a listed-company obligation, while the Q2 numbers provide the more immediate operating reference. For investors, the key contrast is visible in the data: revenue rose 11.87 percent sequentially, while net income increased 34.26 percent.

Stock remains below yearly high

Blau Farmaceutica stock stood at BRL 10.26 on B3 on September 24, 2026, with a market capitalization of BRL 2,369,905,700. Its 52-week range was BRL 8.28 to BRL 14.50, placing the latest price below the annual high while remaining above the low.